The estimated Net Worth of Peter Soparkar is at least $1.89 Million dollars as of 15 March 2023. Mr. Soparkar owns over 13,360 units of Adverum Biotechnologies Inc stock worth over $1,869,214 and over the last 5 years he sold ADVM stock worth over $24,657. In addition, he makes $0 as Chief legal officer at Adverum Biotechnologies Inc.
Peter has made over 5 trades of the Adverum Biotechnologies Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 13,360 units of ADVM stock worth $10,421 on 15 March 2023.
The largest trade he's ever made was buying 25,000 units of Adverum Biotechnologies Inc stock on 8 December 2021 worth over $47,750. On average, Peter trades about 5,419 units every 63 days since 2019. As of 15 March 2023 he still owns at least 265,891 units of Adverum Biotechnologies Inc stock.
You can see the complete history of Mr. Soparkar stock trades at the bottom of the page.
Peter Soparkar J.D. serves as Chief legal officer of the Company. Mr. Soparkar has over 15 years of legal experience, including corporate development, corporate governance, legal, regulatory, commercial, and public compliance activities, for biotechnology companies as well as at a leading international law firm. Prior to joining Adverum, Mr. Soparkar was chief legal officer and head of human resources at Counsyl, Inc., a privately held genetic diagnostics company, where he also served as corporate secretary and head of compliance. He was instrumental in negotiating and executing the sale of Counsyl to Myriad Genetics in 2018. From 2006 - 2016, Mr. Soparkar was at Jazz Pharmaceuticals, where he led the legal team's support of company operations and other business matters, including delivering on numerous debt and equity financings and four landmark transactions which included the launched tender-offer of Celator, the acquisitions of Italy-based Gentium, UK based EUSA Pharma, and the acquisition of and inversion into Ireland-based Azur Pharma. Prior to Jazz, Mr. Soparkar worked at Latham & Watkins in London and San Francisco, with a practice spanning international and domestic markets, as well as private and public transactions. He received a J.D. from New York University and a B.A. in economics and politics from Oberlin College.
Peter Soparkar is 49, he's been the Chief legal officer of Adverum Biotechnologies Inc since 2019. There are 13 older and 4 younger executives at Adverum Biotechnologies Inc. The oldest executive at Adverum Biotechnologies Inc is Richard Spivey, 69, who is the Independent Director.
Peter's mailing address filed with the SEC is C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY, CA, 94063.
Over the last 9 years, insiders at Adverum Biotechnologies Inc have traded over $1,591,374 worth of Adverum Biotechnologies Inc stock and bought 912,973 units worth $4,153,055 . The most active insiders traders include Patrick Machado, Braden Michael Leonard, and Thomas Woiwode. On average, Adverum Biotechnologies Inc executives and independent directors trade stock every 40 days with the average trade being worth of $200,186. The most recent stock trade was executed by Braden Michael Leonard on 30 July 2024, trading 85,800 units of ADVM stock currently worth $613,470.
adverum (nasdaq: advm) is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. we are advancing the development of a robust pipeline of gene therapies that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (a1at) deficiency and hereditary angioedema (hae) as well as wet age-related macular degeneration (wamd). leveraging our next-generation adeno-associated virus (aav)-based directed evolution platform, we generate gene therapies designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.
Adverum Biotechnologies Inc executives and other stock owners filed with the SEC include: